Close Menu

NEW YORK (GenomeWeb) – Danaher today reported that its fourth quarter revenues rose nearly 13 percent year over year.

The company said revenues increased to $5.88 billion for the three months ended Dec. 31, 2015, from $5.22 billion a year ago, but it missed analysts' consensus estimate of $6.00 billion in revenues for the quarter.

The firm's net earnings for the quarter were $688.6 million, or $.99 per share, compared to $661.7 million, or $.92 per share, for Q4 2014. Its adjusted earnings per share was $1.27 for the quarter, matching the consensus Wall Street estimate.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Wall Street Journal reports that Russia's announcement of a coronavirus vaccine approval was met with concern as safety testing has not yet been completed.

New Scientist writes there aren't much data available on the accuracy of the two rapid COVID-19 tests the UK plans to roll out.

In PNAS this week: downstream effect of oncoprotein fusion, epigenetic changes influence tRNAs in colon cancer, and more.

Nature News reports that recent proposed changes to the US National Science Foundation have raised concerns about a shift away from the agency's focus on basic research.